MediciNova, Inc. (MNOV)
NASDAQ: MNOV · Real-Time Price · USD
1.395
-0.005 (-0.36%)
At close: Nov 13, 2026, 4:00 PM EST
1.390
-0.005 (-0.36%)
After-hours: Nov 13, 2026, 4:15 PM EST
MediciNova Revenue
MediciNova had revenue of $138.56K in the quarter ending September 30, 2026, with 12.35% growth. This brings the company's total for the last twelve months to $935.72K. In the year 2025, MediciNova had annual revenue of $409.66K. That makes MediciNova the 43,730th largest company in the world by revenue and 6,122nd in the United States.
Revenue (ttm)
$935.72K
Revenue Growth
+262.80%
P/S Ratio
73.38
Revenue / Employee
$155,953
Employees
6
Market Cap
68.66M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 409.66K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 4.04M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 6.00M | 5.20M | 647.99% |
| Dec 31, 2012 | 802.58K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | 263.88K | -540.19K | -67.18% |
| Dec 31, 2005 | 804.07K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 148.22M |
| Gossamer Bio | 78.42M |
| Fortress Biotech | 68.47M |
| Champions Oncology | 60.66M |
| Verrica Pharmaceuticals | 30.32M |
| Nutriband | 1.62M |
MNOV News
- 1 day ago - MediciNova Quarterly report: Q3 2026 - Filings
- 4 weeks ago - MediciNova CEO provides update on results from Phase 2 trial of MN-001 - TheFly
- 5 weeks ago - MediciNova to Participate in the Maxim Growth Summit - GlobeNewsWire
- 6 weeks ago - MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001 - TheFly
- 6 weeks ago - MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) - GlobeNewsWire
- 7 weeks ago - MediciNova completes LPLV in Phase 2b/3 clinical trial evaluating MN-166 - TheFly
- 7 weeks ago - MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) - GlobeNewsWire
- 1 month ago - MediciNova initiated with a Buy at Roth Capital - TheFly